STAAR Surgical Co. (NASDAQ:STAA) jumped 20.07% to $25.07 in after-hours trading on Wednesday after reporting preliminary first-quarter 2026 net sales of more than $90 million, up from $42.6 million in the same period last year.
China, Americas Drive Growth
Interim Co-CEO and CFO Deborah Andrews said China, the company’s largest market, fueled most of the increase, with double-digit growth in the Americas. She added that higher sales, paired with a streamlined cost structure, should boost adjusted EBITDA.
“These results deliver on two of the three core objectives outlined in our Shareholder Letter earlier this year—Revenue Growth and Profit Expansion—and though early in the year, are indicators of the overall good health of our business,” said Andrews.
Global Challenges Persist
The California-based medical device company said sales in the Middle East, Europe, Africa and the Asia-Pacific region fell due to geopolitical and macroeconomic pressures.
Andrews also cautioned that global conditions remain volatile and the company is providing no forward guidance.
In the last quarter, reported in early March, the company posted an EPS of -$0.13, missing the analyst estimate of $0.11 and revenue of $57.80 million, below the estimate of $75.29 million.
Staar Surgical is scheduled to report earnings on May 6.
Trading Metrics, Technical Analysis
Staar Surgical has a market capitalization of $1.03 billion, with a 52-week high of $30.81 and a 52-week low of $14.69.
The Relative Strength Index (RSI) of STAA stands at 63.16.
The small-cap stock has gained 31.57% over the past 12 months, reflecting investor optimism.
Currently, the stock of the manufacturer of implantable lenses is positioned near the lower end of its 52-week range, roughly 38.41% above the 52-week low.
Price Action: STAA closed the regular session at $20.88, up 31.57%, according to Benzinga Pro.
Benzinga’s Edge Stock Rankings indicate that STAA is experiencing long-term consolidation along with medium and short-term upward movement.
Photo Courtesy: Piotr Swat on Shutterstock.com
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Recent Comments